Elevated inflammatory cytokine levels in bone marrow graft rejection

Area of Science:

• Immunology
• Hematology
• Transplantation Medicine

Background:

• Graft rejection and failure are significant challenges in allogeneic bone marrow transplantation (BMT).
• Cytokines are implicated in the inflammatory and immune responses contributing to allograft rejection.

Purpose of the Study:

• To evaluate inflammatory cytokine levels in patients with graft rejection (GR) following BMT.
• To investigate the association between specific cytokine levels and the occurrence and timing of graft rejection.

Main Methods:

• Analyzed inflammatory cytokine levels (TNF, IL-6, IL-1) in 12 patients with GR and 25 controls using sensitive immunoassays.
• Defined graft rejection by marrow hypoplasia and absence of donor cells post-BMT.
• Compared cytokine levels between GR patients and controls, and between early (<35 days) and late (>35 days) rejection.

Main Results:

• Tumor necrosis factor (TNF) and interleukin-6 (IL-6) levels were significantly higher in GR patients compared to controls (P < 0.05).
• Elevated TNF and IL-6 were more pronounced in early rejection compared to late rejection (P < 0.049 and P < 0.006, respectively).
• Sustained high TNF levels correlated with poor engraftment outcomes, while decreasing TNF levels were observed in patients with stable engraftment after retransplant.

Conclusions:

• A majority of patients with graft rejection exhibit elevated levels of inflammatory cytokines, specifically TNF and IL-6.
• Dysregulation of these inflammatory cytokines appears to be involved in the pathogenesis of graft rejection after BMT.
• Cytokine profiling may offer insights into predicting BMT outcomes and guiding therapeutic strategies.